Who owns Bioxcel Therapeutics Inc?
- Ticker: BTAI
- CUSIP Number: 09075p105
Tip: Access positions for across all investors
Analyze quarterly positions in Bioxcel Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Bioxcel Therapeutics stock
Who bought or sold Bioxcel Therapeutics Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| FMR | 2.5M | $7.0M | -8% | Mar 2024 |
|
| BlackRock | 1.3M | $3.7M | 2% | Mar 2024 |
|
| Vanguard Group | 1.1M | $3.1M | 1% | Mar 2024 |
|
| Ameriprise Financial | 579k | $1.6M | -13% | Mar 2024 |
|
| Geode Capital Management | 458k | $1.3M | 8% | Mar 2024 |
|
| Armistice Capital | 371k | $1.0M | 100% | Mar 2024 |
|
| Beacon Pointe Advisors | 302k | $890k | 0% | Dec 2023 |
|
| Susquehanna International | 289k | $815k | -38% | Mar 2024 |
|
| Morgan Stanley | 222k | $627k | 9% | Mar 2024 |
|
| Northern Trust | 212k | $597k | -6% | Mar 2024 |
|
| Charles Schwab Investment Management | 191k | $539k | 2% | Mar 2024 |
|
| UBS Group | 147k | $415k | 205% | Mar 2024 |
|
| Citadel Advisors | 130k | $367k | -14% | Mar 2024 |
|
| Wells Fargo & Company | 123k | $347k | 58% | Mar 2024 |
|
| Bank of New York Mellon | 123k | $347k | -3% | Mar 2024 |
|
| Castleview Partners | 97k | $274k | 100% | Mar 2024 |
|
| Pennant Investors | 84k | $237k | 100% | Mar 2024 |
|
| Bank Of Montreal | 60k | $171k | -33% | Mar 2024 |
|
| Tocqueville Asset Management | 48k | $136k | -4% | Mar 2024 |
|
| Bank of America Corporation | 47k | $134k | -55% | Mar 2024 |
|
| Millennium Management | 45k | $127k | -49% | Mar 2024 |
|
| Thrivent Financial for Lutherans | 40k | $113k | 100% | Mar 2024 |
|
| Cambridge Investment Research Advisors | 38k | $107k | 0% | Mar 2024 |
|
| Hennion & Walsh Asset Management | 37k | $106k | 2% | Mar 2024 |
|
| Wellington Management Company | 37k | $109k | 0% | Dec 2023 |
|
| Davenport & Co | 34k | $97k | -3% | Mar 2024 |
|
| XTX Topco | 31k | $88k | -7% | Mar 2024 |
|
| Alliancebernstein | 30k | $89k | -16% | Dec 2023 |
|
| Rhumbline Advisers | 30k | $84k | 2% | Mar 2024 |
|
| Goldman Sachs Group | 23k | $64k | 19% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 22k | $61k | -7% | Mar 2024 |
|
| Raymond James & Associates | 19k | $52k | -2% | Mar 2024 |
|
| Us Bancorp | 18k | $51k | 0% | Mar 2024 |
|
| Capital Investment Advisory Services | 18k | $50k | 0% | Mar 2024 |
|
| Deutsche Bank Aktiengesellschaft | 18k | $49k | 0% | Mar 2024 |
|
| SeaCrest Wealth Management | 17k | $49k | -5% | Mar 2024 |
|
| Barclays | 15k | $41k | -47% | Mar 2024 |
|
| Simplex Trading | 14k | $40k | 100% | Mar 2024 |
|
| Virtu Financial | 14k | $39k | -76% | Mar 2024 |
|
| Creative Planning | 13k | $37k | -35% | Mar 2024 |
|
| Branch Banking & Trust Company | 11k | $31k | 0% | Mar 2024 |
|
| Apollon Wealth Management | 10k | $29k | -3% | Mar 2024 |
|
| American International | 10k | $30k | 0% | Dec 2023 |
|
| Jpmorgan Chase & Co | 8.9k | $25k | -30% | Mar 2024 |
|
| Zurcher Kantonalbank | 7.6k | $22k | -3% | Mar 2024 |
|
| Tower Research Capital | 4.6k | $13k | 13% | Mar 2024 |
|
| AllSquare Wealth Management | 4.5k | $13k | 0% | Mar 2024 |
|
| Citigroup | 3.5k | $9.9k | 22% | Mar 2024 |
|
| Cutler | 3.0k | $8.0k | -3% | Mar 2024 |
|
| Washington Trust Advisors | 2.6k | $7.3k | 0% | Mar 2024 |
|
| California State Teachers Retirement System | 2.4k | $6.7k | -89% | Mar 2024 |
|
| Legal & General Group | 2.0k | $5.7k | -33% | Mar 2024 |
|
| National Bank Of Canada /fi/ | 1.9k | $5.5k | 60% | Dec 2023 |
|
| Royal Bank of Canada | 1.4k | $4.5k | -78% | Mar 2024 |
|
| Summit Investment Advisors | 1.4k | $3.8k | 0% | Mar 2024 |
|
| Advisor Group Holdings | 1.1k | $3.2k | 163% | Mar 2024 |
|
| Armstrong Advisory Group | 1.0k | $3.0k | 0% | Mar 2024 |
|
| Amalgamated Bank | 697.00 | $2.0k | -75% | Mar 2024 |
|
| Toth Financial Advisory Corporation | 500.00 | $1.4k | 0% | Mar 2024 |
|
| Goss Wealth Management | 500.00 | $1.4k | 0% | Mar 2024 |
|
| Russell Investments | 344.00 | $970.011200 | 291% | Mar 2024 |
|
| Northwestern Mutual Wealth Management Company | 340.00 | $959.004000 | -80% | Mar 2024 |
|
| Massmutual Trust | 297.00 | $837.985500 | 100% | Mar 2024 |
|
| New York State Common Retirement Fund | 273.00 | $999.999000 | 0% | Mar 2024 |
|
| Federation des caisses Desjardins du Quebec | 113.00 | $318.999000 | 100% | Mar 2024 |
|
| Pnc Financial Services | 107.00 | $301.996800 | -89% | Mar 2024 |
|
| Farther Finance Advisors | 82.00 | $231.002200 | 100% | Mar 2024 |
|
| Capital Advisors | 33.00 | $0 | 100% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 4.00 | $11.000000 | 100% | Mar 2024 |
|
Who sold out of Bioxcel Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Adage Capital Partners GP | Sep 2023 | 200k | $506k |
| Arete Wealth Advisors | Dec 2023 | 109k | $322k |
| Squarepoint Ops | Dec 2023 | 57k | $168k |
| D. E. Shaw & Co | Dec 2023 | 42k | $125k |
| Group One Trading | Sep 2023 | 39k | $98k |
| Connective Capital Management | Dec 2023 | 33k | $97k |
| Jane Street | Dec 2023 | 31k | $92k |
| Y-Intercept | Sep 2023 | 28k | $70k |
| Engineers Gate Manager | Sep 2023 | 22k | $56k |
| Nuveen Asset Management | Sep 2023 | 15k | $38k |
| Crossmark Global Holdings | Sep 2023 | 13k | $43k |
| Qube Research & Technologies | Sep 2023 | 7.4k | $19k |
| Quantbot Technologies | Sep 2023 | 2.1k | $5.3k |